Cipla
CIPLA · Pharma > Pharmaceuticals & Drugs · Chairman: Y K Hamied · MD: Umang Vohra · Listing date: Oct. 27, 1994 · Employees: 25672 · Mumbai · http://www.cipla.com

Stock Price vs Company Growth
1d
3.1%
1w
6.4%
1m
7.3%
3m
0.3%
6m
15.1%
1y
57.3%
5y
22.0%
10y
14.7%
all
11.2%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

1,443 3.1%
1,318
1,519
Company Overview

Sales
25,774 Cr
Growth: 12.1%
Profit after Tax
4,122 Cr
Growth: 11.1%
Large Cap
1,16,531 Cr
P/E: 28.3x
Industry P/E: 36.0x
Fundamentals

Sales (Cr) ₹ 25,774
Growth 12.1%
EBITDA 24.4%
P/S 4.5x
Dividend 0.8%
P/E 28.3x
Book Value ₹ 331
PEG Ratio 2.3x
ROE 16.0%
P/B 4.4x
Shareholding Pattern

Institutions
Sbi Mutual Fund
3.45 %
Government Pension Fund Global
2.36 %
Life Insurance Corporation Of India
2.27 %
Icici Prudential Mutual Fund
1.68 %
Hdfc Mutual Fund
1.19 %
Promoters
Yusuf Khwaja Hamied
20.36 %
Sophie Ahmed
5.71 %
Mustafa Khwaja Hamied
4.29 %
Samina Hamied
2.22 %
Kamil Hamied
1.36 %
Others
Nps Trust
1.51 %
Icici Prudential Life Insurance Company Limited
0.93 %
Increase    Decrease    No change
Company Profile Detailed

The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.ProductsGenerics and branded genericsSpecialtyConsumer healthAwards:2013:Ernst & Young awarded Dr. Y K Hamied with the Lifetime Achievement Award of the year 2013Dr.
Investors (284)
Followers (44)